Out of the 20 BRCA1/2 positive patients, 17 were diagnosed with ovarian serous adenocarcinoma (85 %), whereas the other three with adenocarcinoma endometroides (15 %). This evidence concerns the gene BRCA1 and adenocarcinoma.